Invitrogen Corporation today announced preliminary results for its first quarter ended March 31, 2006. Revenues for the first quarter increased 12% to $309 million versus the same period last year. Sales were lower than anticipated by approximately 3% due to lower than expected performance in its US Bioproduction and Japan businesses. Revenue performance in Europe, US research, and emerging markets were strong.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=533748)